Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gaucher disease.

Pascal Guggenbuhl1, Bernard Grosbois, Gérard Chalès

  • 1Rheumatology Department, Hôpital Sud, Rennes Teaching Hospital, Rennes, France; INSERM U522, IFR 140, Rennes1, Rennes, France.

Joint Bone Spine
|November 13, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brown tumors evolution.

Joint bone spine·2026
Same author

Investigating synovial trace elements as diagnostic markers in acute septic arthritis: an exploratory study.

Clinical rheumatology·2026
Same author

Prognostic Value of Combining Serum Tryptase and Bone Mineral Density in Predicting Fractures in Systemic Mastocytosis.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

More on bone microarchitecture and volumetric BMD in men and women with PLS3 gene variants assessed with HR-pQCT.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025
Same author

EULAR 2025 classification criteria for haemochromatosis arthropathy.

Annals of the rheumatic diseases·2025
Same author

[Microcrystalline arthropathies].

La Revue du praticien·2025
Same journal

Answer to Elbaz et al.

Joint bone spine·2026
Same journal

Greater trochanteric bursal distension with intra-bursal rice bodies: an unusual MRI presentation.

Joint bone spine·2026
Same journal

Evaluating the Impact of a Rheumatologist-led Comorbidity Review in Patients with Inflammatory Arthritis.

Joint bone spine·2026
Same journal

What cumulative glucocorticoid dose should trigger sparing strategies in polymyalgia rheumatica?

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Joint bone spine·2026
Same journal

Multimodal imaging evaluation of the entheses in spondyloarthritis.

Joint bone spine·2026
See all related articles

Gaucher disease is a metabolic disorder caused by beta-glucocerebrosidase deficiency, leading to substrate accumulation. Diagnosis involves enzyme assays and genetic testing, with treatments improving patient outcomes.

Area of Science:

  • Genetics and Metabolic Disorders
  • Lysosomal Storage Diseases
  • Rare Genetic Diseases

Background:

  • Gaucher disease is an inherited autosomal recessive metabolic defect.
  • Deficiency of beta-glucocerebrosidase causes glucocerebroside accumulation, primarily in the liver, spleen, and bone marrow.
  • Osteoarticular manifestations are common and contribute significantly to morbidity.

Purpose of the Study:

  • To provide a comprehensive overview of Gaucher disease, including its types, clinical manifestations, diagnosis, and treatment.
  • To highlight the genetic basis and specific mutations associated with different Gaucher disease types.
  • To discuss current and emerging therapeutic strategies for managing Gaucher disease.

Main Methods:

  • Diagnosis relies on beta-glucocerebrosidase enzyme assays and bone marrow examination.

Related Experiment Videos

  • Genetic analysis identifies specific mutations (e.g., N370S, L444P) linked to disease subtypes.
  • Biomarkers like chitotriosidase and CCL18 are used to assess macrophage activation.

    • Main Results:

    • Gaucher disease presents in three types, with Type 1 being most common, characterized by cytopenia and organomegaly.
    • Types 2 and 3 involve neurological damage, with Type 2 patients rarely surviving past two years.
    • Bone involvement affects 70-100% of cases, manifesting as osteopenia, fractures, and osteonecrosis.
    • Increased risk of myeloma and Parkinson-like syndromes are noted in Type 1.
    • Enzyme replacement therapy (imiglucerase) and substrate reduction therapy (miglustat) have improved management.

    Conclusions:

    • Gaucher disease management has advanced significantly with targeted therapies.
    • Genetic mutations correlate with specific clinical phenotypes, aiding in prognosis.
    • Future treatments like gene therapy and chemical chaperone therapy show promise for Gaucher disease patients.